1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow Biliary Tract Cancers: new trials by email Literature Review of Biliary Tract Cancers trials Research Report on Biliary Tract Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Pembrolizumab, Lenvatinib - Advanced Solid Tumors, Triple Negative Breast Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 611 | 2019-02-12 | 2026-05-04 |
Biliary Tract Neoplasms (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Adnexal Diseases (1) · Astrocytoma (1) · Biliary Tract Diseases (1) · Breast Diseases (1) · Breast Neoplasms (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genital Diseases (1)
lenvatinib (1) · pembrolizumab (1)
Argentina (1) · Australia (1) · Canada (1) · Chile (1) · Colombia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Russia (1) · South Korea (1) · Spain (1) · Switzerland (1) · Taiwan (1) · Thailand (1)
PMID 38718741, PMID 39031824, PMID 40808295, PMID 41747221, PMID 41763955
2018 (1)